Clinical Trial Update: A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating SP-02L in relapsed or refractory peripheral T-cell lymphoma in Korea has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• SP-02L

Snippet

Sponsor: Solasia Pharma K.K. | Conditions: Peripheral T-cell Lymphoma | Phase 1 | Status: COMPLETED